PDS Biotechnology Co. (NASDAQ:PDSB) to Post Q1 2024 Earnings of ($0.40) Per Share, B. Riley Forecasts

PDS Biotechnology Co. (NASDAQ:PDSB) – Analysts at B. Riley issued their Q1 2024 EPS estimates for PDS Biotechnology in a note issued to investors on Thursday, March 28th. B. Riley analyst M. Mamtani anticipates that the company will post earnings of ($0.40) per share for the quarter. B. Riley currently has a “Buy” rating and a $11.00 target price on the stock. The consensus estimate for PDS Biotechnology’s current full-year earnings is ($1.54) per share.

PDSB has been the subject of several other research reports. StockNews.com cut shares of PDS Biotechnology from a “hold” rating to a “sell” rating in a report on Saturday, March 16th. HC Wainwright reissued a “buy” rating and set a $21.00 target price on shares of PDS Biotechnology in a report on Wednesday. Finally, Cantor Fitzgerald reissued an “overweight” rating on shares of PDS Biotechnology in a report on Friday, January 12th. One analyst has rated the stock with a sell rating and four have assigned a buy rating to the company’s stock. According to data from MarketBeat.com, PDS Biotechnology currently has an average rating of “Moderate Buy” and a consensus price target of $17.33.

PDS Biotechnology Trading Up 2.9 %

NASDAQ:PDSB opened at $3.96 on Friday. The company has a current ratio of 6.21, a quick ratio of 6.21 and a debt-to-equity ratio of 0.96. The firm has a fifty day simple moving average of $5.25 and a 200-day simple moving average of $5.09. PDS Biotechnology has a 12 month low of $3.61 and a 12 month high of $10.27. The company has a market capitalization of $123.20 million, a P/E ratio of -2.87 and a beta of 1.72.

Institutional Inflows and Outflows

A number of large investors have recently modified their holdings of PDSB. Oppenheimer & Co. Inc. raised its position in shares of PDS Biotechnology by 78.6% in the first quarter. Oppenheimer & Co. Inc. now owns 25,000 shares of the company’s stock worth $155,000 after acquiring an additional 11,000 shares during the period. BlackRock Inc. raised its position in shares of PDS Biotechnology by 1.0% during the 1st quarter. BlackRock Inc. now owns 435,604 shares of the company’s stock worth $2,697,000 after purchasing an additional 4,199 shares during the last quarter. Dimensional Fund Advisors LP raised its position in shares of PDS Biotechnology by 99.9% during the 1st quarter. Dimensional Fund Advisors LP now owns 69,628 shares of the company’s stock worth $431,000 after purchasing an additional 34,797 shares during the last quarter. Vanguard Group Inc. raised its position in shares of PDS Biotechnology by 7.8% during the 1st quarter. Vanguard Group Inc. now owns 1,093,885 shares of the company’s stock worth $6,771,000 after purchasing an additional 79,025 shares during the last quarter. Finally, Renaissance Technologies LLC raised its position in shares of PDS Biotechnology by 49.5% during the 1st quarter. Renaissance Technologies LLC now owns 665,037 shares of the company’s stock worth $4,117,000 after purchasing an additional 220,300 shares during the last quarter. Institutional investors and hedge funds own 26.84% of the company’s stock.

About PDS Biotechnology

PDS Biotechnology Corporation, a clinical-stage biopharmaceutical company, focuses on developing multifunctional cancer immunotherapies. Its lead product candidate is PDS0101 (HPV16), which is in Phase II clinical trial provides a first line treatment for the recurrent/metastatic head and neck cancer, and human papillomavirus associated malignancies.